Lars Erik Kristensen (Former)
1 – 56 of 56
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity : 52-Week Post Hoc Results from SPIRIT-H2H
(
- Contribution to journal › Article
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
-
Mark
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
(
- Contribution to journal › Article
- 2021
-
Mark
Chronic Pain and Assessment of Pain Sensitivity in Patients With Axial Spondyloarthritis : Results From the SPARTAKUS Cohort
(
- Contribution to journal › Article
- 2020
-
Mark
Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls : Is it an overlooked comorbidity?
(
- Contribution to journal › Letter
-
Mark
The implications of an aging population and increased obesity for knee arthroplasty rates in Sweden : a register-based study
(
- Contribution to journal › Article
- 2019
-
Mark
Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
- 2018
-
Mark
Protocol for evaluating and implementing a pragmatic value-based healthcare management model for patients with inflammatory arthritis : A Danish population-based regional cohort and qualitative implementation study
(
- Contribution to journal › Article
-
Mark
Patient-Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics-Treated Patients With Rheumatoid Arthritis
(
- Contribution to journal › Article
-
Mark
Non-pharmacological Effects in Switching Medication : The Nocebo Effect in Switching from Originator to Biosimilar Agent
(
- Contribution to journal › Article
-
Mark
Burden of rheumatoid arthritis in the Nordic region, 1990-2015 : a comparative analysis using the Global Burden of Disease Study 2015
(
- Contribution to journal › Article
- 2017
-
Mark
EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy : A prospective observational study of patients registered in the south Swedish SSATG registry
(
- Contribution to journal › Article
-
Mark
Work disability in newly diagnosed patients with primary sjögren syndrome
(
- Contribution to journal › Article
-
Mark
Cancer risk in patients with spondyloarthritis treated with TNF inhibitors : A collaborative study from the ARTIS and DANBIO registers
(
- Contribution to journal › Article
-
Mark
Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy : A population-based regional cohort study from southern Sweden
(
- Contribution to journal › Article
-
Mark
Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
(
- Contribution to journal › Article
- 2016
-
Mark
Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Mortality in ankylosing spondylitis: results from a nationwide population-based study.
(
- Contribution to journal › Article
-
Mark
Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal : A Prospective Observational Cohort Study from Southern Sweden
(
- Contribution to journal › Article
-
Mark
Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis : Observational Data from Southern Sweden
(
- Contribution to journal › Article
- 2015
-
Mark
Safety of etoricoxib, celecoxib and non-selective NSAIDs in Ankylosing spondylitis and other Spondyloarthritis patients: A Swedish national population based cohort study.
(
- Contribution to journal › Article
-
Mark
Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register
(
- Contribution to journal › Article
-
Mark
Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register.
(
- Contribution to journal › Article
-
Mark
The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
(
- Contribution to journal › Article
-
Mark
Work Disability in Early Systemic Sclerosis: A Longitudinal Population-based Cohort Study.
(
- Contribution to journal › Article
-
Mark
Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients - baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
(
- Contribution to journal › Article
-
Mark
Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
(
- Contribution to journal › Article
-
Mark
Surgical interventions for nephrolithiasis in ankylosing spondylitis and the general population.
(
- Contribution to journal › Article
-
Mark
The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study.
(
- Contribution to journal › Article
-
Mark
Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
(
- Contribution to journal › Article
- 2014
-
Mark
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
(
- Contribution to journal › Article
-
Mark
Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects.
(
- Contribution to journal › Article
-
Mark
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.
(
- Contribution to journal › Article
-
Mark
Is Swollen to Tender Joint Count Ratio a New and Useful Clinical Marker for Biologic Drug Response in Rheumatoid Arthritis? Results From a Swedish Cohort
(
- Contribution to journal › Article
-
Mark
Efficacy and drug survival of anti-tumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden.
(
- Contribution to journal › Article
- 2013
-
Mark
The prevalence of moderate to severe radiographic sacroiliitis and the correlation with health status in elderly Swedish men - The MrOS study.
(
- Contribution to journal › Article
-
Mark
Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
(
- Contribution to journal › Article
- 2012
-
Mark
Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.
(
- Contribution to journal › Article
- 2011
-
Mark
The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials.
(
- Contribution to journal › Article
-
Mark
National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
(
- Contribution to journal › Article
- 2010
-
Mark
Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during seven years in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Open access publishing. And now, e-publication bias
(
- Contribution to journal › Letter
-
Mark
Utility-based outcomes made easy: The number needed per QALY gained (NNQ). Observational cohort study from Southern Sweden of TNF blockade in inflammatory arthritis.
(
- Contribution to journal › Article
-
Mark
Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register
(
- Contribution to journal › Article
- 2009
-
Mark
Six and 12 Weeks Treatment Response Predicts Continuation of Tumor Necrosis Factor Blockade in Rheumatoid Arthritis: An Observational Cohort Study from Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
(
- Contribution to journal › Article
- 2008
-
Mark
Health utilities improvement during TNF blockade in chronic arthritis occurs early in the treatment course, results from an eight year observational study in southern Sweden
2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals In Arthritis and Rheumatism 58(9). p.552-552(
- Contribution to journal › Published meeting abstract
-
Mark
Anti-TNF treatment of chronic arthritis in clinical practice. New assessment method and predictors of efficacy and tolerability.
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
- 2007
-
Mark
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
(
- Contribution to journal › Article
- 2006
-
Mark
The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Myocarditis in adult-onset Still's disease despite significant immunosuppressive therapy.
(
- Contribution to journal › Letter
-
Mark
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
(
- Contribution to journal › Article